1.Brenseke, B, Prater, MR, Bahamonde, J, Gutierrez, JC. Current thoughts on maternal nutrition and fetal programming of the metabolic syndrome. J Pregnancy. 2013; 2013, 368461.
2.Gluckman, PD, Hanson, MA, Beedle, AS, Spencer, HG. Predictive adaptive responses in perspective. Trends Endocrinol Metab. 2008; 19, 109–110.
3.Hales, CN, Barker, DJ. The thrifty phenotype hypothesis. Br Med Bull. 2001; 60, 5–20.
4.Barker, DJ, Osmond, C, Golding, J, Kuh, D, Wadsworth, ME. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ. 1989; 298, 564–567.
5.Wadhwa, PD, Buss, C, Entringer, S, Swanson, JM. Developmental origins of health and disease: brief history of the approach and current focus on epigenetic mechanisms. Semin Reprod Med. 2009; 27, 358–368.
6.Hoppe, CC, Evans, RG, Moritz, KM, et al. Combined prenatal and postnatal protein restriction influences adult kidney structure, function, and arterial pressure. Am J Physiol Regul Integr Comp Physiol. 2007; 292, R462–R469.
7.Wintour, EM, Moritz, KM, Johnson, K, et al. Reduced nephron number in adult sheep, hypertensive as a result of prenatal glucocorticoid treatment. J Physiol. 2003; 549, 929–935.
8.Luyckx, VA, Brenner, BM. Low birth weight, nephron number, and kidney disease. Kidney Int Suppl. 2005; 97, S68–S77.
9.Langley-Evans, SC, Sherman, RC, Welham, SJ, et al. Intrauterine programming of hypertension: the role of the renin-angiotensin system. Biochem Soc Trans. 1999; 27, 88–93.
10.Rasch, R, Skriver, E, Woods, LL. The role of the RAS in programming of adult hypertension. Acta Physiol Scand. 2004; 181, 537–542.
11.Richter, VF, Briffa, JF, Moritz, KM, Wlodek, ME, Hryciw, DH. The role of maternal nutrition, metabolic function and the placenta in developmental programming of renal dysfunction. Clin Exp Pharmacol Physiol. 2016; 43, 135–141.
12.Segovia, SA, Vickers, MH, Gray, C, Reynolds, CM. Maternal obesity, inflammation, and developmental programming. Biomed Res Int. 2014; 418975.
13.Stewart, T, Jung, FF, Manning, J, Vehaskari, VM. Kidney immune cell infiltration and oxidative stress contribute to prenatally programmed hypertension. Kidney Int. 2005; 68, 2180–2188.
14.Gray, C, Li, M, Reynolds, CM, Vickers, MH. Pre-Weaning Growth Hormone Treatment Reverses Hypertension and Endothelial Dysfunction in Adult Male Offspring of Mothers Undernourished during Pregnancy. PLoS ONE. 2013; 8, e53505.
15.Gray, C, Li, M, Reynolds, CM, Vickers, MH. Let-7 miRNA profiles are associated with the reversal of left ventricular hypertrophy and hypertension in adult male offspring from mothers undernourished during pregnancy following pre-weaning growth hormone treatment. Endocrinology. 2014; 155, 4808–4817.
16.Reynolds, CM, Li, M, Gray, C, Vickers, MH. Pre-weaning Growth Hormone Treatment Ameliorates Adipose Tissue Insulin Resistance and Inflammation in Adult Male Offspring Following Maternal Undernutrition. Endocrinology. 2013; 154(8), 2676–2686.
17.Reynolds, CM, Li, M, Gray, C, Vickers, MH. Pre-Weaning Growth Hormone Treatment Ameliorates Bone Marrow Macrophage Inflammation in Adult Male Rat Offspring following Maternal Undernutrition. PLoS ONE. 2013; 8, e68262.
18.Hammerman, MR, Miller, SB. Effects of growth hormone and insulin-like growth factor I on renal growth and function. J Pediatr. 1997; 131, S17–S19.
19.Koch, JM, Wilmoth, TA, Wilson, ME. Periconceptional growth hormone treatment alters fetal growth and development in lambs. J Anim Sci. 2010; 88, 1619–1625.
20.Setia, S, Sridhar, MG. Changes in GH/IGF-1 axis in intrauterine growth retardation: consequences of fetal programming? Horm Metab Res. 2009; 41, 791–798.
21.Brennan, KA, Olson, DM, Symonds, ME. Maternal nutrient restriction alters renal development and blood pressure regulation of the offspring. Proc Nutr Soc. 2006; 65, 116–124.
22.Hammerman, MR, Miller, SB. The growth hormone insulin-like growth factor axis in kidney revisited. Am J Physiol. 1993; 265, F1–F14.
23.Kamenicky, P, Mazziotti, G, Lombes, M, Giustina, A, Chanson, P. Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. Endocr Rev. 2014; 35, 234–281, P.
24.Hirschberg, R. Effects of growth hormone and IGF-I on glomerular ultrafiltration in growth hormone-deficient rats. Regul Pept. 1993; 48, 241–250.
25.Palmeiro, CR, Anand, R, Dardi, IK, et al. Growth hormone and the cardiovascular system. Cardiol Rev. 2012; 20, 197–207.
26.Lombardi, G, Di Somma, C, Grasso, LF, et al. The cardiovascular system in growth hormone excess and growth hormone deficiency. J Endocrinol Invest. 2012; 35, 1021–1029.
27.Schmittgen, TD, Livak, KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3, 1101–1108.
28.Huang, L, Haylor, JL, Hau, Z, et al. Transglutaminase inhibition ameliorates experimental diabetic nephropathy. Kidney Int. 2009; 76, 383–394.
29.Li, M, Reynolds, CM, Gray, C, Vickers, MH. Preweaning GH Treatment Normalizes Body Growth Trajectory and Reverses Metabolic Dysregulation in Adult Offspring After Maternal Undernutrition. Endocrinology. 2015; 156, 3228–3238.
30.Landgraf, MA, Martinez, LL, Rastelli, VM, et al. Intrauterine undernutrition in rats interferes with leukocyte migration, decreasing adhesion molecule expression in leukocytes and endothelial cells. J Nutr. 2005; 135, 1480–1485.
31.Khraibi, AA. Association between disturbances in the immune system and hypertension. Am J Hypertens. 1991; 4, 635–641.
32.Donate-Correa, J, Martin-Nunez, E, Muros-de-Fuentes, M, Mora-Fernandez, C, Navarro-Gonzalez, JF. Inflammatory cytokines in diabetic nephropathy. J Diabetes Res. 2015; 2015, 948417.
33.Ho, AW, Wong, CK, Lam, CW. Tumor necrosis factor-alpha up-regulates the expression of CCL2 and adhesion molecules of human proximal tubular epithelial cells through MAPK signaling pathways. Immunobiology. 2008; 213, 533–544.
34.Frank, PG, Lisanti, MP. ICAM-1: role in inflammation and in the regulation of vascular permeability. Am J Physiol Heart Circ Physiol. 2008; 295, H926–H927.
35.Rudemiller, NP, Crowley, SD. The role of chemokines in hypertension and consequent target organ damage. Pharmacol Res. 2017; 119, 404–411.
36.Kashyap, S, Warner, GM, Hartono, SP, et al. Blockade of CCR2 reduces macrophage influx and development of chronic renal damage in murine renovascular hypertension. Am J Physiol Renal Physiol. 2016; 310, F372–F384. https://doi.org/10.1152/ajprenal.00131.2015. 37.Ishibashi, M, Hiasa, K, Zhao, Q, et al. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circ Res. 2004; 94, 1203–1210. https://doi.org/10.1161/01.res.0000126924.23467.a3.
38.Usui, M, Egashira, K, Tomita, H, et al. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation. 2000; 101, 305–310.
39.Miravete, M, Dissard, R, Klein, J, et al. Renal tubular fluid shear stress facilitates monocyte activation toward inflammatory macrophages. Am J Physiol Renal Physiol. 2012; 302, F1409–F1417.
40.Hilgers, KF, Hartner, A, Porst, M, et al. Monocyte chemoattractant protein-1 and macrophage infiltration in hypertensive kidney injury. Kidney Int. 2000; 58, 2408–2419.
41.Taal, MW, Zandi-Nejad, K, Weening, B, et al. Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney. Kidney Int. 2000; 58, 1664–1676.
42.Blasi, ER, Rocha, R, Rudolph, AE, et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003; 63, 1791–1800.
43.Perry, MA, Granger, DN. Role of CD11/CD18 in shear rate-dependent leukocyte-endothelial cell interactions in cat mesenteric venules. J Clin Invest. 1991; 87, 1798–1804.
44.Barreiro, O, Martin, P, Gonzalez-Amaro, R, Sanchez-Madrid, F. Molecular cues guiding inflammatory responses. Cardiovasc Res. 2010; 86, 174–182.
45.Ojeda, NB, Grigore, D, Alexander, BT. Developmental programming of hypertension: insight from animal models of nutritional manipulation. Hypertension. 2008; 52, 44–50.
46.Langley-Evans, SC, Welham, SJ, Jackson, AA. Fetal exposure to a maternal low protein diet impairs nephrogenesis and promotes hypertension in the rat. Life Sci. 1999; 64, 965–974.
47.Chen, CM, Chou, HC. Effects of maternal undernutrition on glomerular ultrastructure in rat offspring. Pediatr Neonatol. 2009; 50, 50–53.
48.Schreuder, MF, Nyengaard, JR, Remmers, F, van Wijk, JA, Delemarre-van de Waal, HA. Postnatal food restriction in the rat as a model for a low nephron endowment. Am J Physiol Renal Physiol. 2006; 291, F1104–F1107.
49.Serri, O, St-Jacques, P, Sartippour, M, Renier, G. Alterations of monocyte function in patients with growth hormone (GH) deficiency: effect of substitutive GH therapy. J Clin Endocrinol Metab. 1999; 84, 58–63.
50.Andreassen, M, Frystyk, J, Faber, J, Kristensen, LO. GH activity and markers of inflammation: a crossover study in healthy volunteers treated with GH and a GH receptor antagonist. Eur J Endocrinol. 2012; 166, 811–819.
51.Deepak, D, Daousi, C, Javadpour, M, et al. The influence of growth hormone replacement on peripheral inflammatory and cardiovascular risk markers in adults with severe growth hormone deficiency. Growth Horm IGF Res. 2010; 20, 220–225.
52.Chen, Y, Sood, S, Krishnamurthy, VM, Rotwein, P, Rabkin, R. Endotoxin-induced growth hormone resistance in skeletal muscle. Endocrinology. 2009; 150, 3620–3626.
53.Aurensanz Clemente, E, Ayerza Casas, A, Samper Villagrasa, P, Ruiz Frontera, P, Bueno Lozano, G. Evaluation of cardiac function in a group of small for gestational age school-age children treated with growth hormone. Med Clin. 2017; 148, 101–106.
54.Sas, T, Mulder, P, Hokken-Koelega, A. Body composition, blood pressure, and lipid metabolism before and during long-term growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency. J Clin Endocrinol Metab. 2000; 85, 3786–3792.
55.Pawlikowska-Haddal, A. Growth hormone therapy with norditropin (somatropin) in growth hormone deficiency. Expert Opin Biol Ther. 2013; 13, 927–932.
56.Stochholm, K, Johannsson, G. Reviewing the safety of GH replacement therapy in adults. Growth Horm IGF Res. 2015; 25, 149–157.
57.Carroll, PV, Van den Berghe, G. Safety aspects of pharmacological GH therapy in adults. Growth Horm IGF Res. 2001; 11, 166–172.
58.Whitney, JL, Bilkan, CM, Sandberg, K, Myers, AK, Mulroney, SE. Growth hormone exacerbates diabetic renal damage in male but not female rats. Biol Sex Differ. 2013; 4, 12.
59.Flyvbjerg, A, Bennett, WF, et al. Compensatory renal growth in uninephrectomized adult mice is growth hormone dependent. Kidney Int. 1999; 56, 2048–2054.
60.Flyvbjerg, A. The role of growth hormone in the pathogenesis of diabetic kidney disease. Pediatr Endocrinol Rev. 2004; 1, 525–529.
61.Bellush, LL, Doublier, S, Holland, AN, et al. Protection against diabetes-induced nephropathy in growth hormone receptor/binding protein gene-disrupted mice. Endocrinology. 2000; 141, 163–168.